Expanded Access Protocol Using 131I-MIBG
NCT01590680 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-02-28
Summary
Protocol JDI2007-01 is an Expanded Access Protocol with therapeutic 131I-MIBG for patients with neuroblastoma or pheochromocytoma / paraganglioma, who otherwise do not qualify for available treatments, or where approved treatment is not commercially available.
Conditions
- Neuroblastoma
- Pheochromocytoma
- Paraganglioma
Interventions
- RADIATION
-
I-131 MIBG
The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
Sponsors & Collaborators
-
Jubilant DraxImage Inc.
lead INDUSTRY
Eligibility
- Min Age
- 12 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
NCT01370330 ·Status: AVAILABLE
-
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179086 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
NCT01413503 ·Status: COMPLETED ·Phase: PHASE2
-
Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
NCT01502917 ·Status: COMPLETED ·Phase: PHASE1
-
Radiation Therapy in Treating Patients With Glioblastoma
NCT00019058 ·Status: COMPLETED ·Phase: PHASE1
-
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
NCT03506139 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
NCT02359565 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
NCT00128635 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
NCT02014844 ·Status: COMPLETED ·Phase: PHASE2
-
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
NCT04121455 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Response-based Treatment of High-risk Neuroblastoma
NCT02771743 ·Status: UNKNOWN ·Phase: PHASE2
-
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
NCT05630209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
NCT00004017 ·Status: COMPLETED ·Phase: PHASE2
-
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
NCT04253015 ·Status: RECRUITING
-
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
NCT04998864 ·Status: COMPLETED
-
Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas
NCT00005602 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma
NCT02866747 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma
NCT00037011 ·Status: COMPLETED ·Phase: PHASE1
-
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NCT03180502 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Next Generation Personalized Neuroblastoma Therapy
NCT02780128 ·Status: TERMINATED ·Phase: PHASE1
-
Personalized Radiation Therapy for GBM
NCT03477513 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
NCT02607124 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
NCT05737212 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
NCT00969722 ·Status: TERMINATED ·Phase: PHASE2
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
NCT01466686 ·Status: COMPLETED ·Phase: PHASE2